Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹12 Cr
Revenue (TTM)
₹54 Cr
Net Profit (TTM)
₹1 Cr
ROE
6.8 %
ROCE
12.6 %
P/E Ratio
11.4
P/B Ratio
0.8
Industry P/E
115.07
EV/EBITDA
7
Div. Yield
0 %
Debt to Equity
0.6
Book Value
₹39
EPS
₹2.6
Face value
10
Shares outstanding
4,020,486
CFO
₹-0.35 Cr
EBITDA
₹11.47 Cr
Net Profit
₹4.84 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Saroja Pharma Ind
| -26.5 | -12.1 | -26.5 | -29.1 | -- | -- | -- |
|
BSE Commodities
| -4.9 | -8.2 | -6.3 | 5.0 | 15.1 | 11.3 | 15.5 |
|
Company
|
2025
|
2024
|
|---|---|---|
|
Saroja Pharma Ind
| -31.4 | 13.1 |
|
BSE Small Cap
| -6.6 | 29.0 |
|
BSE Commodities
| 12.5 | 8.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
29.4 | 11.8 | 53.7 | 1.0 | -- | 6.8 | 11.4 | 0.8 |
| 15.9 | 729.1 | 307.3 | 2.6 | 1.5 | 5 | 294.6 | 8.7 | |
| 110.5 | 50.9 | 52.3 | 1.5 | -3.7 | 4.1 | 34.1 | 1.0 | |
| 8.2 | 20.1 | 89.0 | 0.2 | -0.6 | 1.5 | 115.1 | 1.7 | |
| 154.4 | 97.5 | 18.1 | -1.7 | -108.5 | -0.4 | -- | 0.2 | |
| 1.9 | 6.7 | 0.0 | -0.3 | -- | -- | -- | 0.2 | |
| 15.4 | 20.5 | 0.5 | -7.2 | -250.1 | -- | -- | -0.3 | |
| 25.0 | 8.2 | 4.5 | 0.2 | 4.8 | 9.4 | 35.4 | 5.6 | |
| 95.1 | 671.1 | 78.8 | 19.8 | -6.6 | 0.7 | 33.8 | 0.2 | |
| 189.9 | 349.7 | 645.5 | 19.1 | 2.8 | 15.4 | 18.3 | 2.8 |
No Review & Analysis are available.
Pharma APIs
Incorporated
2019
Chairman
Biju Nair
Managing Director
Biju Nair
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Saroja Pharma Industries India Ltd’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Saroja Pharma Industries India Ltd is ₹29.40 (NSE) as of 02-Apr-2026 15:28 IST. Saroja Pharma Industries India Ltd has given a return of -29.07% in the last 1 years.
The P/E ratio of Saroja Pharma Industries India Ltd is 11.43 times as on 01-Apr-2026, a 90 discount to its peers’ median range of 115.07 times.
The P/B ratio of Saroja Pharma Industries India Ltd is 0.75 times as on 01-Apr-2026, a 23 discount to its peers’ median range of 0.97 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
14.68
|
0.97
|
|
2024
|
16.07
|
0.96
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Saroja Pharma Industries India Ltd are Rs 60.00 and Rs 0.00 as of 03-Apr-2026.
Saroja Pharma Industries India Ltd has a market capitalisation of ₹ 12 Cr as on 01-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Saroja Pharma Industries India Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.